A/Texas for Flu
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand the body's response to a flu infection, specifically the H3N2 strain. Participants will be intentionally exposed to the flu to study symptom development and the immune response. Researchers will monitor blood and nasal swab samples before and after infection to determine if antibodies affect illness severity. This trial may suit healthy non-smokers without recent respiratory issues or significant medical conditions. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to contribute to groundbreaking insights.
Do I have to stop taking my current medications for the trial?
Yes, you will need to stop taking certain medications, including specific flu treatments, aspirin, intranasal steroids, decongestants, antihistamines, and NSAIDs, at least 7 days before and during your stay in the inpatient unit, unless approved by the investigator.
Is there any evidence suggesting that this treatment is likely to be safe for humans?
Research has shown that the flu strain A/Texas/71/2017 (H3N2) is generally safe. In earlier studies, a single dose of this strain successfully caused an infection in over 70% of participants, indicating it worked as expected. Importantly, participants found the side effects manageable and not severe.
This study is in an early phase, focusing on checking safety in people. While detailed information on side effects is not yet available, its current testing phase indicates it has passed some initial safety checks. Participants will be closely monitored to ensure any reactions are quickly addressed.12345Why do researchers think this study treatment might be promising?
Unlike the standard flu vaccines that are typically derived from inactivated or attenuated virus strains, the A/Texas treatment uses a specific strain of the influenza virus, RG-A/Texas/71/2017. Researchers are excited about this treatment because it targets a newer variant of the flu virus, potentially offering more effective protection against recent strains. Additionally, by focusing on a single dose administration, it may simplify the vaccination process and improve patient compliance. This innovative approach could lead to better prevention strategies during flu season, especially in rapidly changing flu landscapes.
What evidence suggests that this treatment might be an effective treatment for flu?
Research has shown that flu vaccines, including those similar to A/Texas, have mixed effectiveness. Some studies indicate that these vaccines can prevent millions of flu cases and hospitalizations each year. For example, estimates suggest that flu shots have prevented about 7.1 million flu cases and 3.7 million hospitalizations in the U.S. However, vaccine effectiveness can vary by age group and flu season. Reports have noted reduced effectiveness in certain years, such as the 2017–18 season, particularly for older adults. While A/Texas is being tested in this trial, past vaccines have demonstrated their ability to reduce the severity and spread of the flu.678910
Who Is on the Research Team?
Daniel F. Hoft, MD, PhD
Principal Investigator
Saint Louis University Center for Vaccine Development
Are You a Good Fit for This Trial?
This study is for healthy individuals who will be intentionally infected with the flu to observe how their bodies respond. Participants must stay in a medical facility for at least 10 days and complete daily health diaries. They'll have blood tests and nasal swabs taken before and after infection to monitor immune responses.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Inpatient Challenge
Participants are admitted to the inpatient unit and receive the influenza challenge
Post-Challenge Monitoring
Participants are monitored for symptoms and viral shedding, with daily assessments and potential treatment if still shedding virus
Follow-up
Participants are monitored for safety and effectiveness after treatment, with scheduled visits and a final phone call
What Are the Treatments Tested in This Trial?
Interventions
- A/Texas
Trial Overview
The trial involves infecting participants with an H3N2 flu strain, known as A/Texas, to study symptom patterns and immune response timing. Researchers aim to determine if pre-existing antibodies affect the severity of illness or provide protection against infection.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
One dose of RG-A/Texas/71/2017 Influenza Virus
Find a Clinic Near You
Who Is Running the Clinical Trial?
Daniel Hoft, MD, PhD
Lead Sponsor
Citations
Influenza Vaccine Effectiveness Against ...
Results: The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations ( ...
CDC Seasonal Flu Vaccine Effectiveness Studies
CDC conducts studies each flu season to help determine how well flu vaccines are working. These vaccine effectiveness (VE) studies help regularly assess the ...
Influenza Vaccine Effectiveness Against Medically Attended ...
Statistically significant protection against any influenza was found for all age groups except adults aged 50–64 years. Lack of protection in ...
Effects of Influenza Vaccination in the United States During ...
We estimated that influenza vaccination prevented 7.1 million (95% CrI, 5.4 million–9.3 million) illnesses and 3.7 million (95% CrI, 2.8 million–4.9 million) ...
Interim estimates of 2017–18 seasonal influenza vaccine ...
This report documents the low effectiveness of this year's influenza vaccine, both in normal and immunosuppressed individuals.
Single Dose Texas 2017 (H3N2) Challenge Study
Recombinant H3N2 (A/Texas/71/2017 (H3N2), clade 3C3a) influenza virus at 106 TCID50 dose. This dose has an attack rate of >70%, and a good safety profile ...
Influenza Challenge Study to Determine the Optimal ...
Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain.
Evaluation of correlates of protection against influenza A ...
On average, influenza vaccines have been only approximately 30% effective in preventing influenza A(H3N2) infection, and were ineffective in preventing ...
9.
ctv.veeva.com
ctv.veeva.com/study/influenza-challenge-study-to-determine-the-optimal-infection-dose-and-safety-of-a-recombinant-h3n2Influenza Challenge Study to Determine the Optimal Infection ...
The primary objectives are: 1) To determine the optimal infectious dose of a recombinant influenza virus (A/Texas/71/2017 (H3N2), clade 3C3a) to ...
10.
dshs.texas.gov
dshs.texas.gov/sites/default/files/IDCU/disease/influenza/conference/docs/2017-docs/2a_Hoffman_Influenza-Vaccination-2017.pdfFlu rates/ordering
Influenza Vaccine Safety. 1.Good safety record. 2.Side effects. 3.Vaccine Adverse Event Reporting. System (VAERS). 4.Vaccine Safety Data Link (VSD). Page 20 ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.